A Major Win in the Vaccine Injury Program: Flu Shot Linked to CIDP
Court ruling links flu vaccine to CIDP, signaling broader compensation potential for similar claims in the Vaccine Injury Compensation Program.
In a significant development for vaccine injury law, the U.S. Court of Federal Claims has issued an important entitlement ruling recognizing that the influenza vaccine can cause chronic inflammatory demyelinating polyneuropathy (CIDP). This outcome has meaningful implications for future claims under the National Vaccine Injury Compensation Program (VICP), particularly for individuals suffering from complex neurological injuries following vaccination. The case highlights ongoing legal and medical debates surrounding autoimmune conditions and reinforces a core principle of the Vaccine Act: claimants do not need scientific certainty to prevail—only a medically plausible theory supported by the record.
This case represents an important step forward in how the Vaccine Program evaluates complex neurological injuries following vaccination. At its core, the case involved a petitioner who received an influenza vaccination on November 3, 2023, and subsequently developed progressive neurological symptoms that were ultimately diagnosed as CIDP—a chronic autoimmune condition affecting the peripheral nervous system.
The central factual dispute revolved around onset. Prior to vaccination, the petitioner had reported intermittent, isolated toe numbness. Respondent argued that this symptom represented the early onset of CIDP, effectively attempting to shift the timeline of the disease to before vaccination. However, the evidence told a different story. The pre-vaccination symptom was minor, static, and non-progressive. It was not associated with weakness, functional impairment, or any clinical suspicion of a demyelinating condition.
After vaccination, the petitioner experienced a clear and progressive neurological decline. Symptoms spread beyond the toes, weakness developed, and diagnostic testing confirmed a demyelinating polyneuropathy consistent with CIDP. The Court ultimately rejected the government’s attempt to retroactively characterize the earlier symptom as disease onset and instead credited the post-vaccination clinical progression. This distinction proved decisive.
The legal battle in this case centered on causation under the standard established in Althen v. Secretary of Health & Human Services. Specifically, the dispute focused on whether the petitioner could establish a medically plausible theory connecting the influenza vaccine to CIDP.
Petitioner’s experts advanced a theory grounded in immune-mediated mechanisms, including molecular mimicry and immune dysregulation. They explained how vaccination can, in certain individuals, trigger an autoimmune response that targets peripheral nerves, leading to demyelination and the clinical presentation of CIDP.
Respondent’s expert, by contrast, challenged both the strength of the medical literature and the reliability of the proposed mechanism. The government emphasized that CIDP is distinct from Guillain-Barré Syndrome (GBS), a condition more commonly associated with the flu vaccine, and argued that the scientific evidence linking influenza vaccination specifically to CIDP is limited. Respondent also criticized the reliance on molecular mimicry, arguing that it is frequently invoked without sufficient case-specific support.
The Special Master’s analysis of this issue was candid and, at times, critical of the petitioner’s theory. He observed that the theory was not particularly robust, noting its reliance on the better-established flu–GBS association and the relatively limited CIDP-specific literature. He also reiterated skepticism toward the routine invocation of molecular mimicry when not supported by evidence directly tying the mechanism to the vaccine and the condition at issue.
Yet despite these criticisms, the Court ruled in favor of the petitioner.
Rather than requiring a fully developed, case-specific scientific explanation, the Special Master relied in part on prior Vaccine Program decisions that have accepted some degree of overlap between flu–GBS and flu–CIDP claims. In doing so, the decision reflects an effort to maintain consistency in how similar claims are treated within the Program. Based on that framework, the Court found that the petitioner satisfied the requirements of Althen, even while acknowledging that the theory itself was somewhat “threadbare.”
At the same time, the ruling includes an important caveat. The Special Master made clear that this outcome is not guaranteed in every case going forward. He expressly noted that a stronger evidentiary showing by Respondent—particularly involving CIDP-specific scientific research—could lead to a different result in future cases. In other words, while the door is open, it remains subject to further development of the science and the evidentiary record.
Even with that qualification, the significance of this ruling should not be understated. It reinforces that flu–CIDP claims are viable within the Vaccine Program when supported by a credible factual record and a medically plausible theory. It also confirms that courts will carefully evaluate onset arguments and are willing to reject attempts to recharacterize minor, pre-existing symptoms as evidence of a pre-vaccination condition.
For individuals suffering from CIDP following a flu shot, this decision provides a meaningful path forward. It demonstrates that progressive post-vaccination symptoms, supported by appropriate diagnostic testing, can meet the legal standard for causation—even in the face of scientific uncertainty.
Looking ahead, this ruling is likely to influence how similar cases are litigated and evaluated. It may encourage more claimants to pursue compensation and may also prompt both sides to develop stronger CIDP-specific evidence in future cases.
About David Carney and Green & Schafle LLC
This case was litigated by David Carney of Green & Schafle LLC, a leading law firm in representing individuals injured in the National Vaccine Injury Compensation Program.
Carney has spent over 15 years litigating complex vaccine injury claims, with a particular emphasis on neurological conditions such as Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other immune-mediated disorders. His practice has involved developing medical theories in cases where the science is still evolving—often requiring coordination with leading experts and building records that withstand aggressive challenges from the government.
This ruling reflects that approach. The case required overcoming a common defense strategy—recasting minor, pre-vaccination symptoms as evidence of a pre-existing condition—and advancing a causation theory in an area where the literature is still developing. The outcome reinforces that well-developed records and credible expert support can carry the day, even where the science is not fully settled.
Green & Schafle continues to handle cases involving complex neurological injuries following vaccination and remains at the forefront of litigating emerging issues within the Vaccine Program.
If you or someone you know is dealing with a similar condition following vaccination, it is worth exploring whether a claim may be viable.
📞 215-326-9256
📧 dcarney@greenlegalteam.com